There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance, she said
doi: 10.1016/S0016-5085(24)01827-4 101 LevineISekhriSSchreiber-StainthorpWLockeBDelauOElhawaryMet al
The same active ingredient powers Wegovy, which received FDA approval specifically for obesity treatment in 2021
Many patients carry years of frustration or shame, she said
That number dropped from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina eliminated obesity GLP-1 coverage largely due to state budget constraints
Frequently Asked Questions When will retatrutide be commercially available